Processing

Five technologies that could disrupt pharma manufacturing

Last week, panellists at Pharma Integrates assessed how significant an impact developing technology could make to standard manufacturing processes in the pharma industry. Artificial Intelligence, digitisation, automation, 3D printing, and continuous manufacturing were reviewed during the ‘Applying new technologies to the pharma value chain’ panel discussion, which considered the validity Czytaj więcej…

Processing

AbbVie allows generic manufacture of HCV treatment in 99 countries

Medicines Patent Pool (MPP) entered into a royalty-free licensing agreement with AbbVie to improve global access to its hepatitis C virus (HCV) treatment, Mavyret (glecaprevir/pibrentasvir). With the licensing agreement in place, quality-assured manufacturers will be able to produce and sell generic medicines containing glecaprevir/pibrentasvir (G/P). Improving access​ A spokesperson for Czytaj więcej…

Processing

CDMO partnerships must share risk and balance power, say industry representatives

Agreements between contract manufacturing and development organisations (CDMOs) and pharma companies are often imbalanced, according to Johnson Matthey’s VP of innovator products and solutions, Nick Shackley. At Pharma Integrates in London last week, Shackley told delegates that financial and process incentives, as well as risk responsibility, must be addressed early Czytaj więcej…